The Results of a Study Evaluating a Drug For Mesothelioma Have Been Announced
The company Epizyme has announced the results of a Phase 2 clinical study of its lead candidate drug, tazemetostat, in the treatment of relapsed or refractory malignant mesothelioma with loss…